Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced ...

H. Lundbeck A/S (Lundbeck) today announced that data will be presented for bexicaserin, a novel, highly selective investigational potential treatment ...

Joel Beatty, an analyst from Robert W. Baird, has initiated a new Buy rating on Bright Minds Biosciences (DRUG).Don't Miss our Black Friday ...

Department of Cell Biology, Neurobiology, and Anatomy, Neuroscience Research Center, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, Wisconsin 53226, United States ...

Biased agonism at the 5-HT2C receptor is one of its key features and adds another layer of functional selectivity within a well-validated target. BMB-101 works exclusively via the Gq-protein ...

Search all Neuroscience 2024 abstracts and presentations via the Neuroscience Meeting Planner, or download PDFs of abstracts for all annual meeting presentations. Read about the scientific imagery ...

High-resolution microscopic images of T cells that have been engineered with TGF-beta SNIPRs (shown in red) as they bind to TGF-beta (shown in green). The SNIPRs activate once the receptors fold into ...

Bexicaserin, a 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, has shown to have no impact on 5-HT2B and 5-HT2A receptor subtypes. The US Food and Drug Administration (FDA) granted breakthrough ...

Longboard Pharmaceuticals has commenced the Phase III DEEp OCEAN Study of its investigational oral drug bexicaserin for treating seizures linked to developmental and epileptic encephalopathies ...

In addition, these analogs target serotonin receptors (5-HT2A, 5-HT2B, and 5-HT2C), which are critical in mood regulation and pain perception. The ester modifications introduced in these analogs ...